BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chapman R, Sutton K, Dillon-Murphy D, Patel S, Hilton B, Farkouh R, Wasserman M. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. Vaccine 2020;38:7138-45. [PMID: 32912642 DOI: 10.1016/j.vaccine.2020.08.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wasserman M, Chapman R, Lapidot R, Sutton K, Dillon-Murphy D, Patel S, Chilson E, Snow V, Farkouh R, Pelton S. Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children. Emerg Infect Dis 2021;27:1627-36. [PMID: 34013855 DOI: 10.3201/eid2706.204238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Perdrizet J, Farkouh RA, Horn EK, Hayford K, Sings HL, Wasserman MD. The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines. Expert Rev Vaccines 2022;:1-13. [PMID: 35191368 DOI: 10.1080/14760584.2022.2040989] [Reference Citation Analysis]
3 Horn EK, Wasserman MD, Hall-Murray C, Sings HL, Chapman R, Farkouh RA. Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges. Expert Rev Vaccines 2021;20:1291-309. [PMID: 34424123 DOI: 10.1080/14760584.2021.1971521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marom T, Tshori S, Shefer G, Pitaro J. Pneumococcal Conjugated Vaccines Decreased Acute Otitis Media Burden: A Population-Based Study in Israel. J Pediatr 2021;235:233-238.e3. [PMID: 33894263 DOI: 10.1016/j.jpeds.2021.04.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ghia CJ, Horn EK, Rambhad G, Perdrizet J, Chitale R, Wasserman MD. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India. Infect Dis Ther 2021. [PMID: 34313958 DOI: 10.1007/s40121-021-00498-4] [Reference Citation Analysis]
6 Perdrizet J, Lai YS, Williams S, Struwig VA, Wasserman M. Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia. Infect Dis Ther 2021;10:507-20. [PMID: 33575966 DOI: 10.1007/s40121-021-00409-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wasserman MD, Perdrizet J, Grant L, Hayford K, Singh S, Saharia P, Horn EK, Farkouh RA. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infect Dis Ther 2021;10:2701-20. [PMID: 34633639 DOI: 10.1007/s40121-021-00544-1] [Reference Citation Analysis]
8 Griffith H, Wiese AD, Mitchel EF Jr, Grijalva CG. The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media-Related Antibiotic Use Among Young Children in Tennessee, USA. Open Forum Infect Dis 2022;9:ofac019. [PMID: 35174252 DOI: 10.1093/ofid/ofac019] [Reference Citation Analysis]